ArriVent BioPharma annual return on equity
2024
2025
ArriVent BioPharma Return on Equity (ROE) Growth & History (AVBP)
ArriVent BioPharma's return on equity was −58.88% for fiscal 2025.
View full ArriVent BioPharma company overviewArriVent BioPharma annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −58.88% | +95.22 pp |
| 2024 | 2024-12-31 | −154.10% | — |
ArriVent BioPharma quarterly return on equity
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −14.44% | −0.56 pp |
| Q1 2026 | 2026-03-31 | −13.73% | +14.26 pp |
| Q4 2025 | 2025-12-31 | −11.61% | −3.90 pp |
| Q3 2025 | 2025-09-30 | −12.61% | −5.44 pp |
| Q2 2025 | 2025-06-30 | −13.88% | −6.76 pp |
| Q1 2025 | 2025-03-31 | −27.98% | −6.81 pp |
| Q4 2024 | 2024-12-31 | −7.71% | — |
| Q3 2024 | 2024-09-30 | −7.16% | — |
| Q2 2024 | 2024-06-30 | −7.12% | — |
| Q1 2024 | 2024-03-31 | −21.17% | — |
ArriVent BioPharma return on equity trends
Between the periods ended 2024-12-31 and 2025-12-31, ArriVent BioPharma's return on equity increased from −154.10% to −58.88%, a change of +95.22 percentage points. The latest reported quarter, Q2 2026, shows −14.44%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ArriVent BioPharma source filings ↗